Approval for modifications to the delivery cannulae and the procoagulant and changing the buffering agent in the dilutent to tromethamine usp (tris).  The device, as modified, will be marketed under the trade name duett flowable hemostat device and is indicated for use as adjunct treatment in obtaining hemostasis in sealing residual oozing of tissue tracts of femoral access sites that have been previously closed by suture mediated/collagen-based hemostatic devices.